Brigimadlin is a new oral MDM2-p53 antagonist under investigation as a potential first-line therapy to improve outcomes for patients with advanced or metastatic dedifferentiated liposarcoma.
Katherine E. Taylor, PharmD, MBA, BCOP
Advertisement
Articles by Katherine E. Taylor, PharmD, MBA, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
Young Women With Symptomatic Long COVID At Higher Risk of POTS
3
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
4
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
5
